Back Hoet, JP (1953) 'Gustave Eduoard Laguesse: His demonstration of the significance of the Islands of Langerhans', Diabetes , 2,4, 322-24
Randomized controlled trials have demonstrated that semaglutide treatment does not increase overall cancer risk [3], while observational studies have revealed varying effects across different cancer types [4, 5]
Rodrigues-Martins D, Nunes I, Monteiro MP
In a Phase 3 trial, orforglipron demonstrated a reduction in HbA1c levels by up to 1.6% and an average weight loss of 16 pounds over 40 weeks
The additional receptors in retatrutide increase metabolic rate, enhance fat breakdown, and reduce nausea while providing the same appetite suppression and gastric slowing as Ozempic
In the meantime, some patients on long half-life GLPs are already stretching injections to every 1014 days , especially during maintenance phases